- Home
- EWCZ vs RGNX Comparison
EWCZ vs RGNX Comparison
Compare EWCZ & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWCZ
- RGNX
- Stock Information
- Founded
- EWCZ 2004
- RGNX 2008
- Country
- EWCZ United States
- RGNX United States
- Employees
- EWCZ N/A
- RGNX N/A
- Industry
- EWCZ Package Goods/Cosmetics
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EWCZ Consumer Discretionary
- RGNX Health Care
- Exchange
- EWCZ Nasdaq
- RGNX Nasdaq
- Market Cap
- EWCZ 300.3M
- RGNX 356.7M
- IPO Year
- EWCZ 2021
- RGNX 2015
- Fundamental
- Price
- EWCZ $6.36
- RGNX $6.69
- Analyst Decision
- EWCZ Buy
- RGNX Buy
- Analyst Count
- EWCZ 7
- RGNX 11
- Target Price
- EWCZ $6.64
- RGNX $32.20
- AVG Volume (30 Days)
- EWCZ 360.7K
- RGNX 704.0K
- Earning Date
- EWCZ 03-05-2025
- RGNX 03-07-2025
- Dividend Yield
- EWCZ N/A
- RGNX N/A
- EPS Growth
- EWCZ 62.57
- RGNX N/A
- EPS
- EWCZ 0.23
- RGNX N/A
- Revenue
- EWCZ $223,500,000.00
- RGNX $84,327,000.00
- Revenue This Year
- EWCZ $1.26
- RGNX $2.23
- Revenue Next Year
- EWCZ $2.40
- RGNX $250.77
- P/E Ratio
- EWCZ $28.26
- RGNX N/A
- Revenue Growth
- EWCZ 2.42
- RGNX N/A
- 52 Week Low
- EWCZ $4.80
- RGNX $6.44
- 52 Week High
- EWCZ $15.50
- RGNX $28.80
- Technical
- Relative Strength Index (RSI)
- EWCZ 41.42
- RGNX 33.96
- Support Level
- EWCZ $6.74
- RGNX $6.44
- Resistance Level
- EWCZ $7.60
- RGNX $7.79
- Average True Range (ATR)
- EWCZ 0.33
- RGNX 0.41
- MACD
- EWCZ -0.10
- RGNX -0.10
- Stochastic Oscillator
- EWCZ 5.30
- RGNX 9.54
About EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.